Compare Enovix Corporation (ENVX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Stryker Corporation — how do they compare? Enovix Corporation trades at $4.61 (market cap $1.11B), while Stryker Corporation trades at $329.06 (market cap $121.31B). The key difference: Stryker Corporation is far larger — about 109.3× Enovix Corporation's market cap, and Stryker Corporation pays a 1.11% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | SYK | |
|---|---|---|
Market Cap | $1.11B | $121.31B |
Sector | Technology | Technology |
52-Week High | $15.93 | $403.53 |
52-Week Low | $4.84 | $282.58 |
Enterprise Value | $1.13B | $133.07B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
Stryker (SYK) trades at $330.48, up 6.19% with strong analyst support (74% buy ratings) and a $388.44 consensus price target. The stock shows bearish technical signals despite recent earnings beats in Q3 and Q4 2025, offset by a Q1 2026 miss attributed to a temporary cyber disruption. Fundamentals remain solid with 63.83% gross margins and 13.21% net income margin, while the company continues innovation with Mako robotics expansion and new product launches.
The outlook remains positive given maintained full-year guidance and healthy end-market demand. Key risks include cybersecurity vulnerabilities and competitive pressures, but institutional confidence is high with no sell ratings. The current valuation at 36.63 P/E offers potential upside to the price target, supported by robust cash flow generation and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
